Optimizing transfusion therapy for survivors of Haemoglobin Bart's hydrops fetalis syndrome: Defining the targets for haemoglobin-H fraction and "functional" haemoglobin level

Br J Haematol. 2022 May;197(3):373-376. doi: 10.1111/bjh.18077. Epub 2022 Feb 17.

Abstract

Owing to the unique pathophysiology of anaemia in haemoglobin Bart's hydrops fetalis (HBHF), a transfusion strategy based on beta-thalassemia guidelines is suboptimal for chronically transfused HBHF patients. A more aggressive transfusion aimed at reducing the proportion of non-functional HbH and improving the "functional" haemoglobin (f-Hb) can lead to reduced haemolysis and improved tissue oxygenation. However, the optimal transfusion targets for these parameters are not yet defined. In this retrospective, longitudinal study on four chronically transfused patients with HBHF, we used receiver operating characteristic curves to find a pre-transfusion f-Hb of 106 g/l and a HbH of 16.1% to be the optimal thresholds to achieve a normal soluble transferrin receptor and lactate dehydrogenase, respectively.

Keywords: alpha thalassaemia; erythropoiesis; haemoglobin; haemolysis; iron overload; transfusion.

MeSH terms

  • Female
  • Hemoglobin H
  • Hemoglobins, Abnormal*
  • Humans
  • Hydrops Fetalis / therapy
  • Longitudinal Studies
  • Pregnancy
  • Prenatal Diagnosis
  • Retrospective Studies
  • Survivors
  • alpha-Thalassemia* / therapy

Substances

  • Hemoglobins, Abnormal
  • Hemoglobin H
  • hemoglobin Bart's